Eli Lilly's EloraTZP Shows 23.3% Weight Loss in Mid-Stage Obesity Trials
Key Facts
Eli Lilly's experimental drug EloraTZP showed weight loss of up to 23.3% over 48 weeks in mid-stage trials. Reuters reported that the combination treatment, which targets multiple pathways, outperformed results from tirzepatide alone in overweight patients with type 2 diabetes.
LLY closed at $1151.42 on October 1, 2026, after reaching a session high of $1158.72. The new data intensifies pressure on competitor Novo Nordisk as Eli Lilly demonstrates superior weight loss efficacy compared to existing treatments during this phase of clinical testing.
Latest Updates · 1
- Major·
Update: A new Phase 3 post-hoc analysis for Eli Lilly's oral drug Foundayo demonstrated a 57.00% reduction in predicted type 2 diabetes risk. The data released on October 2, 2026, also showed an 18.00% reduction in cardiovascular disease risk over a 72-week period.